Objective. To analyze the efficacy and safety of submucosal tunnel endoscopic resection (STER) for the treatment of submucosal masses in esophageal muscularis propria. Method. A total of 272 patients with submucosal masses in esophageal muscularis propria diagnosed and treated in our hospital from February 2019 to January 2022 were randomly selected for the study and then were randomly divided into the STER group () and the endoscopic mucosal dissection (ESD) group () according to the random number table method. Patients in the STER and ESD groups were treated with STER and ESD, respectively. The clinical data of patients from the two groups were collected and compared. The clinical effects and the changes of surgery-related indexes of patients after ESD and STER treatment were observed. The safety of ESD and STER was compared. The factors influencing the efficacy of STER treatment for submucosal masses in esophageal muscularis propria were analyzed. Result. There were significant differences between the STER group and the ESD group in terms of tumor size, lesion level, adhesion and surgical approaches (). The effective rates of ESD treatment and STER treatment were 98.53% and 88.97%, respectively. Meanwhile, the effective rates of STER treatment were significantly higher than those in the control group (). In addition, the patients in the STER group had longer operation time, less blood loss, and shorter hospital stay compared with those in the ESD group (). Adverse reactions occurred during ESD treatment and STER treatment included delayed bleeding, adhesion, perforation, and pleural effusion with the total incidence of adverse reactions of 4.41% and 13.97%, respectively. The adverse reactions in STER group were prominently less than these in the ESD group (). Logistic multivariate regression analysis showed that independent risk factors, including tumor size, lesion level, adhesion, and surgical approaches, affected the efficacy of STER in the treatment of submucosal masses in esophageal muscularis propria (). Conclusion. STER is an effective method for the treatment of submucosal masses in esophageal muscularis propria, which can exhibit a good effect with faster postoperative recovery and higher safety, thereby being worthy of clinical application and promotion. Tumor size, lesion level, adhesion, and surgical approaches are all related factors affecting the effect of STER treatment.

中文翻译：

---

黏膜下隧道内镜下切除食管固有肌黏膜下肿块的疗效和安全性分析

客观。分析黏膜下隧道内镜下切除术（STER）治疗食管固有肌层黏膜下肿块的疗效和安全性。方法。随机选取2019年2月至2022年1月在我院诊治的食管固有肌层黏膜下肿块患者272例进行研究，然后随机分为STER组（)和内镜黏膜剥离 (ESD) 组 ()根据随机数表法。STER 和 ESD 组的患者分别接受 STER 和 ESD 治疗。收集并比较两组患者的临床资料。观察ESD和STER治疗后患者的临床疗效及手术相关指标的变化。比较了ESD和STER的安全性。分析影响STER治疗食管固有肌层黏膜下肿块疗效的因素。结果。STER组和ESD组在肿瘤大小、病灶水平、粘连和手术入路方面存在显着差异。）。ESD治疗和STER治疗的有效率分别为98.53%和88.97%。同时，STER治疗有效率显着高于对照组（）。此外，与 ESD 组相比，STER 组患者手术时间更长、失血量更少、住院时间更短。）。ESD治疗和STER治疗期间发生的不良反应包括迟发性出血、粘连、穿孔和胸腔积液，不良反应总发生率分别为4.41%和13.97%。STER组的不良反应明显少于ESD组（）。Logistic多因素回归分析显示，肿瘤大小、病灶水平、粘连和手术入路等独立危险因素影响STER治疗食管固有肌层黏膜下肿块的疗效。）。 结论。STER是治疗食管固有肌层黏膜下肿块的有效方法，疗效好，术后恢复快，安全性高，值得临床推广应用。肿瘤大小、病灶水平、粘连和手术方式都是影响STER治疗效果的相关因素。